再鼎医药(ZLAB)今日盘中股价大幅上涨10.56%，引起了市场的广泛关注。
消息面上，公司宣布其自研靶向DLL3的抗体偶联药物(ADC)Zoci（zocilurtatugpelitecan，原ZL-1310）获得美国FDA授予快速通道资格，用于治疗经一线标准治疗后进展的肺外神经内分泌癌(epNECs)。该疾病为侵袭性强、预后差的恶性肿瘤，目前全球尚无获批的靶向疗法与标准治疗方案，存在巨大的未满足医疗需求。
此外，在2026年AACR年会上公布的Ib/II期注册研究数据显示，Zoci用于多线治疗失败的epNEC患者，客观缓解率(ORR)达到38.2%，且安全性可控。目前，Zoci针对epNEC的临床项目正在推进注册，并已与药监部门沟通注册计划。这一重要的监管进展和积极的临床试验结果，显著增强了市场对公司核心产品研发前景和未来商业化潜力的信心，从而成为推动股价上涨的主要动力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.